The promise of combining CDK4/6 inhibition with hormonal therapy in the first-li

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay, Regina Graul, Amreen Husain, Mansoor Raza Mirza, Brian Slomovitz

Int J Gynecol Cancer. 2023 Oct 31:ijgc-2023-004739. Online ahead of print.

Metastatic or recurrent endometrioid adenocarcinoma of the uterine corpus is often incurable with limited treatment options. First-line treatment often includes cytotoxic chemotherapy, which incurs significant toxicities for many patients. Endometrial cancer, specifically endometrioid cancer, is a hormone-sensitive disease and, while single-agent hormonal therapies have demonstrated clinical benefit, resistance to these agents often leads to the use of chemotherapy. There is a lack of approved endocrine treatment options in the metastatic setting for most recurrent endometrial cancers, representing an unmet clinical need. Emerging evidence suggests that hormonal therapy in combination with other targeted treatments, such as cyclin dependent kinase (CDK)4/6 inhibitors, is well tolerated and effective in select patient populations. We discuss the clinical evidence suggesting that the combination of CDK4/6 inhibitors and hormonal therapy has the potential to represent an important addition to the first-line treatment options for patients with low-grade advanced or recurrent endometrial cancer.

PMID: 37907262  DOI: 10.1136/ijgc-2023-004739

See publication 

Chargement en cours...